Precision biosciences and tiziana life sciences announce exclusive license agreement to evaluate foralumab, a novel, fully human anti-cd3 monoclonal antibody, in conjunction with allogeneic car t candidates for cancer treatment

Precision gains access to tiziana's anti-cd3 antibody, foralumab, to evaluate as a lymphodepletion agent with its allogeneic car t portfolio precision gains access to tiziana's anti-cd3 antibody, foralumab, to evaluate as a lymphodepletion agent with its allogeneic car t portfolio
TLSA Ratings Summary
TLSA Quant Ranking